Genfit S.A. (GNFT)


-0.05 (-0.95%)
Symbol GNFT
Price $4.68
Beta 1.321
Volume Avg. 0.03M
Market Cap 233.137M
Shares () -
52 Week Range 3.01-6.38
1y Target Est -
DCF Unlevered GNFT DCF ->
DCF Levered GNFT LDCF ->
ROE -63.53% Strong Sell
ROA -9.41% Neutral
Operating Margin -
Debt / Equity 136.55% Buy
P/E 3.69 Buy
P/B 1.67 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest GNFT news

NASDAQ Global Select

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.